Semaglutide extended lifespan in old mice

Researchers at the University of California, Berkeley reported in Nature on September 2, 2026 that giving semaglutide to mice late in life extended their median lifespan by 12%, from 742 days in untreated controls to 834 days in treated animals^[1]. The study was done entirely in mice. It is not a human trial, and it does not show that semaglutide slows aging in people.

What the study found

The team, led by Danica Chen at UC Berkeley, began dosing 20 month old female mice with semaglutide, roughly the mouse-age equivalent of a woman in her sixties, and continued treatment for the rest of the animals' lives^{[1] [3]}. Age-matched control mice received saline injections and ate normally. Treated mice lived a median of 92 days longer than controls, and gene-expression analysis of liver tissue showed the treated group overlapping with calorie restriction on several fronts: lower inflammation markers, reduced fat-processing burden, improved genes tied to blood sugar handling, and better protein maintenance^[2].

The treated mice also performed better on functional tests: they balanced longer on a rotating rod, ran farther on a treadmill, solved mazes faster, and had better blood glucose control than untreated controls^[2]. They also showed more exploratory behavior and higher curiosity in open-field testing, both standard proxies researchers use for reduced age-related apathy in mice^[2].

The biology behind the result

At the molecular level, the study reports that late-life semaglutide treatment modulated nutrient-sensing pathways and conserved genetic regulators of aging, the same broad category of biological machinery that calorie restriction is already known to act on^[1]. Semaglutide is a GLP-1 receptor agonist: it mimics a natural gut hormone that tells the pancreas to release insulin and the brain that the stomach is full. That receptor sits in metabolic and appetite-control tissue, which is one reason researchers think a drug built to treat diabetes and obesity might also touch pathways that govern how cells age.

How it compares with cutting calories

In a second arm of the study, the researchers compared semaglutide to a 24% calorie-restricted diet, a well-established way to extend lifespan in lab mice. The semaglutide group matched the calorie-restricted mice on muscle strength and coordination, and did better on exploratory behavior, spatial memory, and glucose regulation^[2]. Unlike the calorie-restricted mice, whose metabolic rate dropped, the semaglutide-treated mice kept a largely unchanged metabolic rate^[2]. Chen described the drug's effect as going beyond a calorie-restriction mimic, while acknowledging the team does not yet know why semaglutide outperformed dieting on the cognitive measures^[2].

What this is not

This is not evidence that semaglutide extends human lifespan. The research was funded by the National Institutes of Health, and the study authors were explicit that the mouse findings do not imply similar results could be achieved in humans, and that clinical studies are needed before anyone can say whether GLP-1 drugs affect human longevity^[3].

It is also worth being precise about what semaglutide is approved for. In the EU and EEA, the EMA authorizes semaglutide (sold as Ozempic and Rybelsus for type-2 diabetes, Wegovy for chronic weight management) strictly for those indications, and it remains prescription-only^[4]. There is no approved anti-aging indication anywhere, and the mouse study is not grounds for anyone to seek semaglutide off-label for that purpose. More on how semaglutide is regulated is on the semaglutide regulation page.

What is still unresolved

The study covered one sex, one strain, and one lab. Because it only tested female mice, the researchers have not yet reported whether male mice show the same effect, and the paper does not include a head-to-head comparison of lifespan between the semaglutide group and the calorie-restricted group, only the functional and biological measures described above^[2]. Chen herself was blunt about the mechanism question: asked why semaglutide beat calorie restriction on the cognitive tests, she said, "the short answer is: we don't know yet"^[2].

Outside researchers are not fully convinced semaglutide is the better intervention. Nir Barzilai of the Albert Einstein College of Medicine, who was not involved in the study, questioned whether calorie restriction alone might still produce the larger lifespan gain, asking, "Maybe calorie restriction increases the lifespan more?"^[2] Rafael de Cabo of the National Institute on Aging offered a more optimistic read, noting that most chronic disease is rooted in aging itself, so if GLP-1 drugs do slow the aging process, broad clinical benefits are what researchers would expect to see^[3]. Independent replication, a male cohort, and eventually a controlled human study are the steps that would need to happen before this finding says anything definitive about human aging.

Where this lands

For now, this is a well-conducted mouse study that adds semaglutide to the small list of compounds shown to affect biological aging pathways in an animal model, not a reason to use semaglutide outside its approved indications. Anyone taking or considering semaglutide for type-2 diabetes or weight management should keep making that decision with a prescribing clinician, based on the approved evidence on the semaglutide page, not on a headline about mice.